Robert DuFresne
Nessuna posizione attualmente
Profilo
Mr. DuFresne brings substantial management experience in the biopharmaceutical industry to his executive role at Zelos Therapeutics.
He has a strong background in deal negotiation, business start-ups, international business, finance, organizational development, marketing, sales, project management, drug development, and corporate strategy.
He is currently on the board of T2C2.
Mr. DuFresne graduated from Harvard University, earning both an MBA (high Honors) and a BA in History.
Precedenti posizioni note di Robert DuFresne
| Società | Posizione | Fine |
|---|---|---|
| PACGEN LIFE SCIENCE CORPORATION | Presidente | 31/10/2008 |
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Corporate Officer/Principal | - |
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Presidente | - |
Formazione di Robert DuFresne
| Harvard University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Health Technology |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
Pacgen Life Science Corp.
 Pacgen Life Science Corp. BiotechnologyHealth Technology Pacgen Life Science Corp. is a life science technology company, which engages in the development and commercialization of biomedical products and services. It specializes in the operation of global commercial platform to market and distribute consumer health products developed by small business enterprises. The company focuses on oral care and skin care commercial rights. Pacgen Life Science was founded by Fred Huang and Chung Yu Wang on April 23, 2004 and is headquartered in Vancouver, Canada. | Health Technology |
- Borsa valori
- Insiders
- Robert DuFresne